For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Cardlytics Inc (NASDAQ: CDLX) was $15.41 for the day, up 1.38% from the previous closing price of $15.20. In other words, the price has increased by $1.38 from its previous closing price. On the day, 0.9 million shares were traded. CDLX stock price reached its highest trading level at $15.88 during the session, while it also had its lowest trading level at $15.11.
Ratios:
Our analysis of CDLX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Craig Hallum on March 15, 2024, Upgraded its rating to Buy and sets its target price to $18 from $10 previously.
On November 29, 2023, Lake Street started tracking the stock assigning a Buy rating and target price of $13.
Wells Fargo Downgraded its Equal Weight to Underweight on September 08, 2022, whereas the target price for the stock was revised from $14 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 24 ’24 when Gupta Amit sold 23,416 shares for $11.91 per share. The transaction valued at 278,885 led to the insider holds 122,676 shares of the business.
Lynton Nicholas Hollmeyer sold 276 shares of CDLX for $3,521 on Apr 23 ’24. The Chief Legal & Privacy Officer now owns 71,761 shares after completing the transaction at $12.76 per share. On Apr 02 ’24, another insider, Temsamani Karim Saad, who serves as the Chief Executive Officer of the company, sold 32,564 shares for $13.69 each. As a result, the insider received 445,801 and left with 344,734 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 742361344 and an Enterprise Value of 853996288. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.40 while its Price-to-Book (P/B) ratio in mrq is 4.54. Its current Enterprise Value per Revenue stands at 2.762 whereas that against EBITDA is -22.951.
Stock Price History:
Over the past 52 weeks, CDLX has reached a high of $20.52, while it has fallen to a 52-week low of $4.94. The 50-Day Moving Average of the stock is 27.54%, while the 200-Day Moving Average is calculated to be 39.32%.
Shares Statistics:
CDLX traded an average of 1.69M shares per day over the past three months and 778820 shares per day over the past ten days. A total of 48.17M shares are outstanding, with a floating share count of 45.32M. Insiders hold about 5.92% of the company’s shares, while institutions hold 62.67% stake in the company. Shares short for CDLX as of 1713139200 were 5780006 with a Short Ratio of 3.43, compared to 1710460800 on 4483071. Therefore, it implies a Short% of Shares Outstanding of 5780006 and a Short% of Float of 14.510000000000002.
Earnings Estimates
The current assessment of Cardlytics Inc (CDLX) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.2, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.06, with high estimates of $0.03 and low estimates of -$0.17.
Analysts are recommending an EPS of between $0.43 and -$0.4 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.4, with 3.0 analysts recommending between $0.82 and -$0.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $72.4M to a low estimate of $70.99M. As of the current estimate, Cardlytics Inc’s year-ago sales were $64.33MFor the next quarter, 3 analysts are estimating revenue of $81.39M. There is a high estimate of $82.4M for the next quarter, whereas the lowest estimate is $80.4M.
A total of 3 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $340.7M, while the lowest revenue estimate was $335M, resulting in an average revenue estimate of $337.79M. In the same quarter a year ago, actual revenue was $309.2MBased on 3 analysts’ estimates, the company’s revenue will be $381.67M in the next fiscal year. The high estimate is $385.25M and the low estimate is $375.97M.
